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SUMMARY
Aim. The aim of this study was to investigate the co-pre-
scribing of 5-antagonists and P-agonists in the community,
and to assess the potential hazards of such co-prescribing.
Methods. The study was set in the population of Tayside,
Scotland (population approximately 400 000), between
January 1993 and March 1993. An automated person-spe-
cific prescribing database was used, which could also be
linked to hospital admissions. Patients who were co-pre-
scribed n-antagonists and p-agonists on the same day or
within 30 days were selected. A model was used to identify
those who showed an asthmatic profile, on the basis of
age, and previous prescribing and hospitalization history,
and for whom the co-prescribing was judged to be particu-
larly hazardous.
Results. Altogether, 0.9% of 15 824 patients who received a
3-antagonist during the study period received a p-agonist
on the same day. This figure increased to 274 (1.7%) for 30-
day co-prescription. A few instances of particularly haz-
ardous co-prescribing were identified, which involved
young people who had previously received prescriptions
for corticosteroids and been hospitalized for asthma.
Conclusion. Potentially hazardous co-prescribing of P-ago-
nists and 3-antagonists occurs despite labelled warnings,
even in patients who appear to be at high risk. These
events are quite rare but probably should not occur at all.
Keywords: co-prescribing; P-antagonists; P-agonists; asth-
ma.
Introduction
SHINCE their introduction in the 1960s, beta-adrenoceptor
blocking drugs (/-antagonists) have been implicated in the
precipitation of problems in asthmatics, including marked reduc-
tion in forced expiratory volume (FEV),-3 wheezing,' 2,48 and
near-fatal7'9"0 and fatal9"0 asthma attacks. Even those /I-antago-
nists such as atenolol, betaxolol, bisoprolol and metoprolol that
have lesser effects on the /2-receptors and airways resistance"
are not /,3-specific and free of such side-effects.'2 Therefore, /3
antagonists are contraindicated in asthmatics'3 and should be pre-
scribed to them only when no other treatment is available.2"'1 If
such treatment is essential, P/-selective antagonists are recom-
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mended over those that are less fiB-selective, such as propranolol.
P-Antagonists should also be avoided in patients who have
chronic obstructive airways disease.2 In particular, /3-antagonists
are contraindicated in patients receiving /2-adrenoceptor stimu-
lants (/3agonists) as they have opposing effects.
The Medicines Monitoring Unit (MEMO) is a university-
based organization that was set up to carry out pharmacoepi-
demiological research in the population of Tayside (population
approximately 400 000).14,15 Data on prescriptions that have been
dispensed in the community are collected and stored on a data-
base. MEMO currently has records of 8 million prescriptions dat-
ing from January 1989. The information can be linked to the hos-
pitalization database for Tayside, which represents records of all
episodes of hospitalization for Tayside residents, with diagnostic
and procedure codes. The record linkage is achieved using the
Community Health Index Number (CHNo.). This is a 10-digit
number allocated to all patients in Tayside when they register
with a GP.
MEMO has strict confidentiality agreements and does not dis-
close person-specific or general practitioner (GP)-specific data
without written agreement from the individuals concerned. For
publication purposes, data from MEMO are considered in aggre-
gate and anonymized form, so that no individual patient or GP
identification is possible.
Using purpose-written software, the prescribing database was
interrogated to investigate patterns of co-prescribing of /3-antago-
nists and ,B-agonists to patients in Tayside likely to have asthma
or chronic obstructive airways disease.
Method
Co-prescribing of /3-antagonists and /3-agonists was investigated
in the population of Tayside between January 1993 and March
1993. To begin with, the number of patients potentially at risk
from co-prescribing was established by determining how many
received prescriptions for /3-antagonists and ,B-agonists during
the time period. The number of co-prescription events was then
determined for these patients.
Two definitions of co-prescribing were used in the study:
(1) Same day co-prescription: /3-antagonist and /3-agonist
prescribed to the same patient on the same day.
(2) Thirty-day co-prescription: /antagonist and /agonist
prescribed to the same patient within a 30-day period.
It was judged that the co-prescribing of /antagonists and /3
agonists was particularly hazardous for patients who were likely
to have asthma. Patients were therefore stratified into their likeli-
hood of having asthma according to the following assumptions:
(1) Patients who had previously received a prescription for
an inhaled corticosteroid were more likely to have asth-
ma rather than chronic obstructive airways disease.
These data were available from August 1992.
(2) Patients were more likely to have asthma if they were
under the age of 45 years, and more likely to have
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chronic obstructive airways disease if they were over
this age.
(3) Patients who had been hospitalized (since January
1980) with a diagnostic code for asthma were likely to
be asthmatic.
The co-prescribing events were also stratified into whether the
,antagonist was /, selective or non-selective, and for the 30-day
co-prescribing analysis whether it was prescribed before or after
the /3agonist.
The hospitalization database was then searched to identify any
evidence of hospital admissions resulting from co-prescribing in
the patients studied.
The results of this study were circulated to all GPs in Tayside
to seek their permission to publish the results. The local medical
committee of the British Medical Association also sent a newslet-
ter to all GPs suggesting that they check their prescribing records
for instances of co-prescribing of ,B-agonists and fantagonists.
Any GPs in Tayside who requested information on co-prescribing
in their patients were supplied with the relevant study data.
Results
Between January 1993 and March 1993, 15 824 patients in
Tayside received prescriptions for 3-antagonists and 16 330 for
,B3agonists.
Table I shows the results of the search for co-prescription of
/3antagonists and /agonists on the same day during this period.
There were 201 instances of co-prescription to 149 of the above
patients. Fifty-three of these patients, seven of whom were below
the age of 45 years, had previously received prescriptions for
corticosteroids. There were eight instances of co-prescribing to
these seven patients, of which half involved a non-selective /3
antagonist. One had previously been admitted to hospital with
asthma.
When the definition of co-prescription was broadened to 30
days (Table 2), 579 instances of co-prescribing to 274 patients
were identified. Ninety-four had previously received prescrip-
tions for corticosteroids and 17 were under the age of 45 years.
These patients had 30 instances of co-prescribing, 20 of which
involved a non-selective /3-antagonist. Two had previously been
admitted to hospital with asthma.
Of those co-prescribing events which did not occur on the
same day (59% of the 203), the /agonist was prescribed first in
over half (59%) and the /antagonist first in 41%.
Table 1. Co-prescription on same day in Tayside, January 1993
to March 1993.
201 events (149 patients)
Prescriptions for corticosteroids?
84 events (53 patients)
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No records of hospital admissions resulting from co-prescrib-
ing were identified in the patients studied.
Discussion
In Tayside, 149 (0.9%) of the 15 824 patients who received a ,/
antagonist between January 1993 and March 1993 received a ,&
agonist on the same day. Within 30 days, this figure increased to
274 (1.7%). The aim of this study was to assess the potential haz-
ards of such co-prescribing. To do this, it was necessary to make
certain assumptions because the precise indications for the drugs
were not known.
There are two possible scenarios within which co-prescribing
could occur. If a patient is not known to be asthmatic and a /3
antagonist is prescribed, asthma symptoms might develop, thus
disclosing asthma. The /antagonist might then be withdrawn
and a /3agonist prescribed. Such prescribing is reasonable. On
the other hand, if a patient is already known to be asthmatic, the
co-prescription of /antagonists and /-agonists is less rational.
For this reason, we defined co-prescribing as hazardous if it
occurred in patients who were likely to have asthma. Given that
use of corticosteroids is recommended in patients even with mild
asthma 1,16 and that differentiation between asthma and chronic
obstructive airways disease can be attributed to age,'7 patients
were considered to be asthmatic if they had received prescrip-
tions for corticosteroids from August 1992 and were under the
age of 45 years. This model for asthma has its limitations, espe-
cially given the availability of recent data only for corticosteroid
prescribing. Therefore, the number of asthmatic patients might
be underestimated. Whether the /antagonist was /3,-selective or
non-selective was also assessed, as was whether there had been
any previous hospitalization episodes for asthma.
Using this rationale, several instances of hazardous prescribing
were identified in young patients who had previously received
therapy for asthma and been admitted to hospital with asthma.
One such example involved a young person who had previously
been admitted to hospital with asthma on three separate occa-
sions, had received prescriptions for corticosteroids, and was
subsequently prescribed a non-selective /antagonist and a /3-
agonist on the same day. Such prescribing seems difficult to jus-
tify, as even the use of a /3,-selective antagonist may precipitate
severe bronchospasm owing to the effect of a relatively small
degree of A2-blockade.
When 30-day co-prescribing was investigated, the /3agonist
was prescribed first in the majority of events. These events can-
Table 2. Co-prescription within 30 days in Tayside, January 1993
to March 1993.
579 events (274 patients)
Prescriptions for corticosteroids?
203 events (94 patients)
Aged <45 years
Eight events (seven patients)
L
.-.
Selective p- Non-selective 13-
antagonist antagonist
Aged >45 years
76 events (46 patients)
Selective 1- Non-selective P-
antagonist antagonist
Aged <45 years
30 events (17 patients)
Selective 1- Non-selective 1-
antagonist antagonist
Aged >45 years
173 events (77 patients)
Selective 1- Non-selective 1-
antagonist antagonist
Four events Four events
(three patients) (four patients)
63 events 13 events
(36 patients) (10 patients)
10 events 20 events 128 events 45 events
(six patients) (11 patients) (53 patients) (24 patients)
Previous hospital admissions for asthma?
One patient One patient One patient
Previous hospital admissions for asthma?
Two patients Three patients Two patients
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not be explained by the presence of asthma being disclosed by
the use of a /3-antagonist.
Data error should be considered in such an automated study.
CHNo. allocation to prescriptions within MEMO has an error
rate of approximately 1%. It could be that a fl-antagonist appear-
ing in the prescribing record of an asthmatic is caused by such
misallocation. However, this is unlikely to account for all the
instances of co-prescribing, especially as many patients experi-
enced more than one co-prescription event and the probability of
the error occurring twice in the same patient is low.
In this study, only a few instances of particularly hazardous
co-prescribing were identified during a 3-month period, none of
which resulted in hospital admissions that could be attributed to
such co-prescribing. Nevertheless, the overall prescribing of ,B
antagonists to asthmatic patients was probably underestimated,
given the limitations of the model for asthma and the definition
of co-prescribing. It could also be argued that such co-prescrib-
ing should not occur at all, and the study perhaps serves as a
reminder of the potential consequences of such actions.
The study also shows how the data in MEMO served as a
resource for local GPs. Many requested information on co-pre-
scribing in their patients and used it for clinical review.
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